Immunocore Holdings plc
For the period ended Jun 30, 2025. Filed Aug 7, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2025 · Filed Aug 7, 2025
IMCR$32.38+2.0%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Cash Flows for the
Condensed Consolidated Statements of Cash Flows
(Unaudited) (In thousands)
| Six Months Ended June 30, | ||
|---|---|---|
| 2025 | 2024 | |
| Cash flows from operating activities | ||
| Net loss | $(5,277) | $(36,052) |
| Adjustments for: | ||
| Share-based compensation expense | 19,522 | 18,964 |
| Depreciation | 1,634 | 2,003 |
| Unrealized foreign exchange (gains) losses, net | (607) | 1,404 |
| Unrealized gains on marketable securities | (10,162) | (4,613) |
| Non-cash lease expense | 1,114 | 864 |
| Other | 1,049 | 951 |
| Changes in assets and liabilities: | ||
| Increase in accounts receivable | (3,341) | (8,861) |
| Decrease (increase) in prepayments and other current assets | 365 | (4,058) |
| (Decrease) increase in accounts payable | (3,587) | 2,164 |
| Increase in accrued expenses | 22,787 | 46,031 |
| Decrease in deferred revenue | (97) | — |
| Decrease in operating lease liabilities | (528) | (1,136) |
| Decrease in other operating assets | 3,527 | 92 |
| Increase in other operating liabilities | — | 1,132 |
| Net cash provided by operating activities | 26,399 | 18,885 |
| Cash flows from investing activities | ||
| Purchase of marketable securities | (30,000) | (350,000) |
| Proceeds from sale of marketable securities | 10,000 | — |
| Purchase of property and equipment | (712) | (761) |
| Net cash used in investing activities | (20,712) | (350,761) |
| Cash flows from financing activities | ||
| Proceeds from exercise of share options | 6,221 | 6,052 |
| Proceeds from issue of convertible loan notes | — | 402,500 |
| Payments for debt issuance costs | — | (13,358) |
| Net cash provided by financing activities | 6,221 | 395,194 |
| Increase in net cash and cash equivalents | 11,908 | 63,318 |
| Net foreign exchange difference on cash held | 20,294 | (959) |
| Cash and cash equivalents at beginning of period | 455,731 | 442,626 |
| Cash and cash equivalents at end of period | $487,933 | $504,985 |
| Supplemental disclosure of cash flow information | ||
| Cash paid for interest | $(5,031) | $(2,442) |
| Cash paid for income taxes, net of refunds | $(1,510) | $(59) |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.